Kerman R H, Van Buren C T, Lewis R M, Kahan B D
Department of Surgery, University of Texas Medical School, Houston.
Clin Transpl. 1988:167-70.
Our data indicate that CsA-P-treated primary recipients of cadaveric donor renal allografts as well as haploidentical living-related donor allograft recipients enjoy prolonged, successful patient and graft survivals whether conditioned with pretransplant transfusions or not. The data are important because they reflect clinical results from a single transplant center wherein the recipients have been immunosuppressed for approximately 7 years with little change in protocol. This is an important point since utilizing maximum therapeutic immunosuppressive efficacy will result in prolonged graft and patient survival.
